deferoxamine has been researched along with Cerebral Ischemia in 24 studies
Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
desferrioxamine B : An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Despite transferrin being the main circulating carrier of iron in body fluids, and iron overload conditions being known to worsen stroke outcome through reactive oxygen species (ROS)-induced damage, the contribution of blood transferrin saturation (TSAT) to stroke brain damage is unknown." | 9.27 | Iron-loaded transferrin (Tf) is detrimental whereas iron-free Tf confers protection against brain ischemia by modifying blood Tf saturation and subsequent neuronal damage. ( Alborch, E; Castelló-Ruiz, M; Castillo, J; Dávalos, A; DeGregorio-Rocasolano, N; García-Yébenes, I; Gasull, T; Guirao, V; Lizasoain, I; Martí-Sistac, O; Millán, M; Ponce, J; Ramos-Cabrer, P; Salom, JB, 2018) |
| "In the present study, the effects of deferoxamine on tissue lactate and malondialdehyde (MDA) levels after cerebral ischemia in rabbits was studied." | 7.72 | Effects of deferoxamine on tissue lactate and malondialdehyde levels in cerebral ischemia. ( Ak, A; Bariskaner, H; Dogan, N; Gurbilek, M; Ustun, ME; Yosunkaya, A, 2003) |
| "Deferoxamine (DFO) is a high-affinity iron chelator approved by the Food and Drug Administration for treating iron overload." | 5.35 | Intranasal deferoxamine provides increased brain exposure and significant protection in rat ischemic stroke. ( Coppes, VG; Frey, WH; Hanson, LR; Hoekman, JD; Marti, DL; Martinez, PM; Matthews, RB; Panter, SS; Rao, RJ; Roeytenberg, A; Sweet, DC, 2009) |
| "Incomplete cerebral ischemia was produced by intracranial pressure elevation for 30 minutes with plasma glucose at 540 +/- 15 mg/dL." | 5.29 | Deferoxamine reduces early metabolic failure associated with severe cerebral ischemic acidosis in dogs. ( Blizzard, KK; Hurn, PD; Koehler, RC; Traystman, RJ, 1995) |
| "Despite transferrin being the main circulating carrier of iron in body fluids, and iron overload conditions being known to worsen stroke outcome through reactive oxygen species (ROS)-induced damage, the contribution of blood transferrin saturation (TSAT) to stroke brain damage is unknown." | 5.27 | Iron-loaded transferrin (Tf) is detrimental whereas iron-free Tf confers protection against brain ischemia by modifying blood Tf saturation and subsequent neuronal damage. ( Alborch, E; Castelló-Ruiz, M; Castillo, J; Dávalos, A; DeGregorio-Rocasolano, N; García-Yébenes, I; Gasull, T; Guirao, V; Lizasoain, I; Martí-Sistac, O; Millán, M; Ponce, J; Ramos-Cabrer, P; Salom, JB, 2018) |
| "In the present study, the effects of deferoxamine on tissue lactate and malondialdehyde (MDA) levels after cerebral ischemia in rabbits was studied." | 3.72 | Effects of deferoxamine on tissue lactate and malondialdehyde levels in cerebral ischemia. ( Ak, A; Bariskaner, H; Dogan, N; Gurbilek, M; Ustun, ME; Yosunkaya, A, 2003) |
| "Deferoxamine (DFO) is a high-affinity iron chelator approved by the Food and Drug Administration for treating iron overload." | 1.35 | Intranasal deferoxamine provides increased brain exposure and significant protection in rat ischemic stroke. ( Coppes, VG; Frey, WH; Hanson, LR; Hoekman, JD; Marti, DL; Martinez, PM; Matthews, RB; Panter, SS; Rao, RJ; Roeytenberg, A; Sweet, DC, 2009) |
| "Rat model of cerebral ischemia was established by middle cerebral artery occlusion with or without DFO administration." | 1.35 | Desferoxamine preconditioning protects against cerebral ischemia in rats by inducing expressions of hypoxia inducible factor 1 alpha and erythropoietin. ( Ding, SJ; Guo, W; Li, YX; Xiao, L; Zhan, Q, 2008) |
| "Incomplete cerebral ischemia was produced by intracranial pressure elevation for 30 minutes with plasma glucose at 540 +/- 15 mg/dL." | 1.29 | Deferoxamine reduces early metabolic failure associated with severe cerebral ischemic acidosis in dogs. ( Blizzard, KK; Hurn, PD; Koehler, RC; Traystman, RJ, 1995) |
| "The area of cerebral infarction was measured at three levels using video imaging methods." | 1.29 | Failure of iron chelators to protect against cerebral infarction in hypoxia-ischemia. ( Davis, J; Fridovich, I; MacMillan, V, 1993) |
| "Animals subjected to cardiac arrest and resuscitation and standard intensive care (SIC) had LMWC iron levels of 37." | 1.27 | Post resuscitation iron delocalization and malondialdehyde production in the brain following prolonged cardiac arrest. ( Aust, SD; Bialek, H; Evans, AT; Huang, RR; Indrieri, RJ; Jacobs, WA; Komara, J; Nayini, NR; White, BC, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (8.33) | 18.7374 |
| 1990's | 11 (45.83) | 18.2507 |
| 2000's | 6 (25.00) | 29.6817 |
| 2010's | 4 (16.67) | 24.3611 |
| 2020's | 1 (4.17) | 2.80 |
| Authors | Studies |
|---|---|
| Liu, H | 1 |
| Schwarting, J | 1 |
| Terpolilli, NA | 1 |
| Nehrkorn, K | 1 |
| Plesnila, N | 1 |
| DeGregorio-Rocasolano, N | 1 |
| Martí-Sistac, O | 1 |
| Ponce, J | 1 |
| Castelló-Ruiz, M | 1 |
| Millán, M | 1 |
| Guirao, V | 1 |
| García-Yébenes, I | 1 |
| Salom, JB | 1 |
| Ramos-Cabrer, P | 1 |
| Alborch, E | 1 |
| Lizasoain, I | 1 |
| Castillo, J | 1 |
| Dávalos, A | 1 |
| Gasull, T | 1 |
| Jones, SM | 1 |
| Novak, AE | 1 |
| Elliott, JP | 1 |
| Egashira, Y | 1 |
| Xi, G | 1 |
| Chaudhary, N | 1 |
| Hua, Y | 1 |
| Pandey, AS | 1 |
| Wilks, MQ | 1 |
| Normandin, MD | 1 |
| Yuan, H | 1 |
| Cho, H | 1 |
| Guo, Y | 1 |
| Herisson, F | 1 |
| Ayata, C | 1 |
| Wooten, DW | 1 |
| El Fakhri, G | 1 |
| Josephson, L | 1 |
| Hanson, LR | 1 |
| Roeytenberg, A | 1 |
| Martinez, PM | 1 |
| Coppes, VG | 1 |
| Sweet, DC | 1 |
| Rao, RJ | 1 |
| Marti, DL | 1 |
| Hoekman, JD | 1 |
| Matthews, RB | 1 |
| Frey, WH | 1 |
| Panter, SS | 1 |
| Liachenko, S | 1 |
| Tang, P | 1 |
| Xu, Y | 1 |
| Bariskaner, H | 1 |
| Ustun, ME | 1 |
| Ak, A | 1 |
| Yosunkaya, A | 1 |
| Dogan, N | 1 |
| Gurbilek, M | 1 |
| Chi, OZ | 1 |
| Hunter, C | 1 |
| Liu, X | 1 |
| Weiss, HR | 1 |
| Li, YX | 1 |
| Ding, SJ | 1 |
| Xiao, L | 1 |
| Guo, W | 1 |
| Zhan, Q | 1 |
| Chu, K | 1 |
| Jung, KH | 1 |
| Kim, SJ | 1 |
| Lee, ST | 1 |
| Kim, J | 1 |
| Park, HK | 1 |
| Song, EC | 1 |
| Kim, SU | 1 |
| Kim, M | 1 |
| Lee, SK | 1 |
| Roh, JK | 1 |
| Hurn, PD | 1 |
| Koehler, RC | 1 |
| Blizzard, KK | 1 |
| Traystman, RJ | 2 |
| Sorrenti, V | 1 |
| Di Giacomo, C | 1 |
| Renis, M | 1 |
| Russo, A | 1 |
| La Delfa, C | 1 |
| Perez-Polo, JR | 1 |
| Vanella, A | 1 |
| Palmer, C | 1 |
| Roberts, RL | 1 |
| Bero, C | 1 |
| MacMillan, V | 1 |
| Fridovich, I | 1 |
| Davis, J | 1 |
| Li, Y | 1 |
| Bickel, KD | 1 |
| Im, MJ | 1 |
| Hu, L | 1 |
| Dellon, AL | 1 |
| Vander Kolk, CA | 1 |
| Manson, PN | 1 |
| Shadid, M | 2 |
| Buonocore, G | 1 |
| Groenendaal, F | 1 |
| Moison, R | 2 |
| Ferrali, M | 1 |
| Berger, HM | 2 |
| van Bel, F | 2 |
| Steendijk, P | 1 |
| Hiltermann, L | 1 |
| Rosenthal, RE | 1 |
| Chanderbhan, R | 1 |
| Marshall, G | 1 |
| Fiskum, G | 1 |
| Soloniuk, DS | 1 |
| Perkins, E | 1 |
| Wilson, JR | 1 |
| Kirsch, JR | 1 |
| Helfaer, MA | 1 |
| Lange, DG | 1 |
| Patt, A | 1 |
| Horesh, IR | 1 |
| Berger, EM | 1 |
| Harken, AH | 1 |
| Repine, JE | 1 |
| Nayini, NR | 1 |
| White, BC | 1 |
| Aust, SD | 1 |
| Huang, RR | 1 |
| Indrieri, RJ | 1 |
| Evans, AT | 1 |
| Bialek, H | 1 |
| Jacobs, WA | 1 |
| Komara, J | 1 |
| Babbs, CF | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Double-blind, Randomized, Placebo Controlled, Dose-finding Phase 2 Clinical Trial of Intravenous Deferoxamine in Patients With Acute Ischemic Stroke Treated With Tissue Plasminogen Activator[NCT00777140] | Phase 2 | 62 participants (Actual) | Interventional | 2008-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for deferoxamine and Cerebral Ischemia
| Article | Year |
|---|---|
Evidence for free radical mechanisms of brain injury resulting from ischemia/reperfusion-induced events.
Topics: Animals; Brain; Brain Injuries; Brain Ischemia; Deferoxamine; Free Radical Scavengers; Free Radicals | 1992 |
Role of iron ions in the genesis of reperfusion injury following successful cardiopulmonary resuscitation: preliminary data and a biochemical hypothesis.
Topics: Animals; Brain Ischemia; Deferoxamine; Free Radicals; Heart Arrest; Humans; Hydroxylation; Ions; Iro | 1985 |
1 trial available for deferoxamine and Cerebral Ischemia
| Article | Year |
|---|---|
Iron-loaded transferrin (Tf) is detrimental whereas iron-free Tf confers protection against brain ischemia by modifying blood Tf saturation and subsequent neuronal damage.
Topics: Animals; Apoproteins; Brain Ischemia; Deferoxamine; Female; Humans; Iron; Iron Overload; Lipid Perox | 2018 |
21 other studies available for deferoxamine and Cerebral Ischemia
| Article | Year |
|---|---|
Scavenging Free Iron Reduces Arteriolar Microvasospasms After Experimental Subarachnoid Hemorrhage.
Topics: Animals; Arterioles; Brain Ischemia; Capillaries; Deferoxamine; Iron; Male; Mice, Inbred C57BL; Side | 2021 |
The role of HIF in cobalt-induced ischemic tolerance.
Topics: Amino Acids, Dicarboxylic; Animals; Astrocytes; Brain Ischemia; Cell Survival; Cells, Cultured; Coba | 2013 |
Acute Brain Injury after Subarachnoid Hemorrhage.
Topics: Acute Disease; Acute-Phase Proteins; Animals; Brain Injuries; Brain Ischemia; Deferoxamine; Hemoglob | 2015 |
Imaging PEG-like nanoprobes in tumor, transient ischemia, and inflammatory disease models.
Topics: Animals; Brain; Brain Ischemia; Carbocyanines; Cell Line, Tumor; Deferoxamine; Female; Inflammation; | 2015 |
Intranasal deferoxamine provides increased brain exposure and significant protection in rat ischemic stroke.
Topics: Administration, Intranasal; Animals; Behavior, Animal; Brain; Brain Ischemia; Deferoxamine; Dose-Res | 2009 |
Deferoxamine improves early postresuscitation reperfusion after prolonged cardiac arrest in rats.
Topics: Animals; Blood Pressure; Brain Ischemia; Cerebrovascular Circulation; Deferoxamine; Heart Arrest; He | 2003 |
Effects of deferoxamine on tissue lactate and malondialdehyde levels in cerebral ischemia.
Topics: Acute Disease; Animals; Brain; Brain Ischemia; Deferoxamine; Electroencephalography; Iron Chelating | 2003 |
Effects of deferoxamine on blood-brain barrier disruption and VEGF in focal cerebral ischemia.
Topics: Aminoisobutyric Acids; Animals; Blood Pressure; Blood-Brain Barrier; Brain Ischemia; Capillary Perme | 2008 |
Desferoxamine preconditioning protects against cerebral ischemia in rats by inducing expressions of hypoxia inducible factor 1 alpha and erythropoietin.
Topics: Animals; Brain Ischemia; Cells, Cultured; Cerebral Infarction; Deferoxamine; Disease Models, Animal; | 2008 |
Transplantation of human neural stem cells protect against ischemia in a preventive mode via hypoxia-inducible factor-1alpha stabilization in the host brain.
Topics: Animals; Brain; Brain Infarction; Brain Ischemia; Chemokine CXCL12; Cyclooxygenase 2; Deferoxamine; | 2008 |
Deferoxamine reduces early metabolic failure associated with severe cerebral ischemic acidosis in dogs.
Topics: Acidosis; Adenosine Triphosphate; Animals; Brain Ischemia; Deferoxamine; Disease Models, Animal; Dog | 1995 |
Lipid peroxidation and survival in rats following cerebral post-ischaemic reperfusion: effect of drugs with different molecular mechanisms.
Topics: Allopurinol; Animals; Antioxidants; Brain Ischemia; Deferoxamine; Diltiazem; Lipid Peroxidation; Mal | 1994 |
Deferoxamine posttreatment reduces ischemic brain injury in neonatal rats.
Topics: Animals; Animals, Newborn; Brain Ischemia; Deferoxamine; Female; Hypoxia, Brain; Male; Rats | 1994 |
Failure of iron chelators to protect against cerebral infarction in hypoxia-ischemia.
Topics: Animals; Brain; Brain Ischemia; Carbon Monoxide; Cerebral Infarction; Deferoxamine; Hypoxia, Brain; | 1993 |
Effects of deferoxamine on ischemia/reperfusion injury after peripheral nerve compression.
Topics: Animals; Blotting, Western; Brain; Brain Ischemia; Deferoxamine; Iron Chelating Agents; Male; Nerve | 1996 |
Effect of deferoxamine and allopurinol on non-protein-bound iron concentrations in plasma and cortical brain tissue of newborn lambs following hypoxia-ischemia.
Topics: Allopurinol; Animals; Animals, Newborn; Brain Ischemia; Cerebral Cortex; Deferoxamine; Hypoxia, Brai | 1998 |
The effect of antioxidative combination therapy on post hypoxic-ischemic perfusion, metabolism, and electrical activity of the newborn brain.
Topics: Allopurinol; Animals; Animals, Newborn; Antioxidants; Asphyxia Neonatorum; Brain; Brain Ischemia; Cy | 1998 |
Prevention of post-ischemic brain lipid conjugated diene production and neurological injury by hydroxyethyl starch-conjugated deferoxamine.
Topics: Alkenes; Animals; Brain Ischemia; Deferoxamine; Free Radicals; Heart Arrest; Hydroxyethyl Starch Der | 1992 |
Use of allopurinol and deferoxamine in cellular protection during ischemia.
Topics: Allopurinol; Animals; Brain Ischemia; Cell Death; Cerebral Infarction; Deferoxamine; Rats | 1992 |
Iron depletion or chelation reduces ischemia/reperfusion-induced edema in gerbil brains.
Topics: Animals; Brain; Brain Chemistry; Brain Edema; Brain Ischemia; Deferoxamine; Female; Gerbillinae; Hem | 1990 |
Post resuscitation iron delocalization and malondialdehyde production in the brain following prolonged cardiac arrest.
Topics: Animals; Brain Ischemia; Deferoxamine; Dogs; Free Radicals; Heart Arrest; Iron Chelating Agents; Lid | 1985 |